罗氟司特片一个疗程价格多少钱？

How much does Roflumilast tablets cost in China?

Roflumilast was successfully developed for the first time by the German company Altana, and currently more sales rights are owned by AstraZeneca. Roflumilast can be used for patients with severe chronic obstructive pulmonary disease (COPD) accompanied by chronic bronchitis and a history of exacerbations to reduce the risk of COPD exacerbations. It was launched in the United States in 2011. However, roflumilast is not currently available in China, and there is no price information published. Patients cannot buy it in regular domestic hospital pharmacies.

It is understood that the current overseas market is affected by exchange rate fluctuations and is not fixed. The current reference price is probably the British AstraZeneca version of roflumilast (direct mail from Germany):

A box of 500μg*30 tablets costs $1,700;

A box of 500μg*90 tablets costs $2850.

How much does a course of Roflumilast tablets cost?

The dosage of Roflumilast tablets is one tablet per day, the dose is 500 micrograms (mcg), which can be taken with or without food. The instructions for roflumilast tablets do not mention how long a course of treatment should be. The duration of use also needs to be determined according to the doctor's instructions. Here, the cost is only calculated based on one month.

According to the usage and dosage of roflumilast, one pill of roflumilast is needed every day, and one box of 500μg*30 tablets is needed for a month; one box of 500μg*90 tablets can last for about 3 months. Relatively speaking, the 2850$ box of 500μg*90 tablets is more cost-effective. Patients in need of roflumilast can obtain it through domestic professional overseas medical service institutions. The medicine can be directly mailed to their homes from Germany, and they can obtain overseas medicine without going abroad. For more details about medicines, you can consult customer service staff to get more secure medicines.

It is a new type of drug for the treatment of COPD. It is a type 4 phosphodiesterase (PDE4) inhibitor. It is suitable for patients with severe COPD to treat cough and phlegm caused by bronchitis, but it is not suitable for another type of COPD, namely primary emphysema. Research suggests: Roflumilast can improve lung function and reduce acute exacerbations in patients with a history of frequent exacerbations and/or hospitalization (the research article was published in the AJRCCM journal in September 2016). It is recommended that patients take medication under the guidance of a doctor and receive symptomatic treatment.

Recommended related articles: